Germany's BioNTech Acquires CureVac to Accelerate Cancer Research Using mRNA Technology
Germany's BioNTech is acquiring CureVac for $1.25 billion to strengthen its mRNA technology platform and accelerate the development of innovative cancer immunotherapies, marking a significant move in biotech research.
Germany's leading biotechnology companies, BioNTech and CureVac, are set to combine their efforts through a $1.25 billion acquisition by BioNTech of CureVac. This strategic move unites two prominent firms specializing in mRNA technology, aiming to advance innovative cancer therapies. BioNTech, renowned for developing the first widely approved COVID-19 vaccine in the West alongside Pfizer, emphasized that this acquisition would enhance their ability to leverage complementary capabilities and cutting-edge technologies.
Both companies have a strong history in developing mRNA-based solutions, which stimulate an immune response by delivering genetic instructions to human cells. While mRNA technology gained prominence during the COVID-19 pandemic, scientists believe its applications extend well beyond infectious diseases, potentially transforming the treatment landscape for numerous illnesses.
BioNTech plans for this acquisition to significantly bolster its immunotherapy programs targeting cancer. The company's CEO, Ugur Sahin, highlighted that this deal is a vital component of their oncology strategy and a step toward setting new standards for cancer care in the future. CureVac's CEO, Alexander Zehnder, added that the acquisition would bring together essential scientific expertise, technological innovations, and manufacturing capabilities in the mRNA field under one roof.
The deal, which is an all-stock agreement, has received unanimous approval from both firms' management and supervisory boards. It is expected to close in 2025, pending regulatory approvals. Both BioNTech and CureVac are listed on the Nasdaq and have a shared history in vaccine development, with BioNTech’s COVID vaccine achieving global success. CureVac, founded 25 years ago by mRNA pioneer Ingmar Hoerr, shifted away from their COVID efforts after less successful trials and even filed patent infringement lawsuits against BioNTech in 2022.
This acquisition marks a significant step in expanding the potential of mRNA technology for cancer treatments and could pave the way for new standards of care in oncology.
Source: https://medicalxpress.com/news/2025-06-germany-biontech-buy-curevac-boost.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Understanding Why Alcohol Policies Often Overlook Those at Highest Risk
Discover why alcohol policies often fail to protect the most at-risk populations and learn how social and structural factors influence alcohol-related harms across different communities.
Early Life Exposure to Dogs and Its Potential to Reduce Genetic Risk of Eczema
New research indicates that early exposure to dogs may protect children genetically predisposed to eczema by influencing immune-related genetic mechanisms, offering potential avenues for prevention.
Fatal Measles Case in Canada: Infant Dies from Virus Contracted at Birth Due to Unvaccinated Mother
A tragic case in Canada highlights the dangers of measles, as an infant born prematurely from an unvaccinated mother succumbs to the virus amid rising outbreaks. Experts stress the importance of vaccination to prevent such tragedies.
